Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1984 3
1986 2
1987 2
1989 1
1990 1
1991 1
1993 2
1994 1
1995 7
1996 1
1997 3
1998 1
1999 2
2000 2
2001 2
2002 1
2003 5
2004 3
2005 9
2006 2
2007 5
2008 7
2009 7
2010 2
2011 5
2012 3
2013 8
2014 13
2015 14
2016 10
2017 12
2018 11
2019 21
2020 19
2021 21
2022 19
2023 20
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Cervical Carcinoma"
Page 1
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Ferris RL, et al. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718784 Free PMC article. Clinical Trial.
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. ...Physical, role, and social functioning was stable in the nivolumab group, …
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy hav …
Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma.
Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L, Han P, Wang Y, Ji D, Gan H, Wei W, Lu Z, Qu N, Hu J, Hu X, Luo Z, Li H, Ji Q, Wang J, Zhang X, Wang YL. Pu W, et al. Nat Commun. 2021 Oct 18;12(1):6058. doi: 10.1038/s41467-021-26343-3. Nat Commun. 2021. PMID: 34663816 Free PMC article.
The tumor ecosystem of papillary thyroid carcinoma (PTC) is poorly characterized. Using single-cell RNA sequencing, we profile transcriptomes of 158,577 cells from 11 patients' paratumors, localized/advanced tumors, initially-treated/recurrent lymph nodes and radioactive i …
The tumor ecosystem of papillary thyroid carcinoma (PTC) is poorly characterized. Using single-cell RNA sequencing, we profile transc …
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Fallahi P, et al. Semin Cancer Biol. 2022 Feb;79:180-196. doi: 10.1016/j.semcancer.2020.11.013. Epub 2020 Nov 26. Semin Cancer Biol. 2022. PMID: 33249201 Review.
In DTC patients, radioactive iodine (RAI) is administered after thyroidectomy. Neck ultrasound, basal and thyroid-stimulating hormone-stimulated thyroglobulin are generally performed every three to six months for the first year, with subsequent intervals depending on initi …
In DTC patients, radioactive iodine (RAI) is administered after thyroidectomy. Neck ultrasound, basal and thyroid-stimulating hormone …
Pembrolizumab in the first-line treatment of advanced head and neck cancer.
de Sousa LG, Ferrarotto R. de Sousa LG, et al. Expert Rev Anticancer Ther. 2021 Dec;21(12):1321-1331. doi: 10.1080/14737140.2021.1996228. Epub 2021 Nov 2. Expert Rev Anticancer Ther. 2021. PMID: 34689660 Review.
INTRODUCTION: Recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis and has limited therapeutic options. PD-1/PD-L1 axis blockade was initially shown to improve outcomes in platinum-refractory H …
INTRODUCTION: Recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognos …
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
Xu Y, Gao Z, Hu R, Wang Y, Wang Y, Su Z, Zhang X, Yang J, Mei M, Ren Y, Li M, Zhou X. Xu Y, et al. J Immunother Cancer. 2021 Oct;9(10):e002699. doi: 10.1136/jitc-2021-002699. J Immunother Cancer. 2021. PMID: 34697216 Free PMC article.
BACKGROUND: Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limited efficacy of anti-epidermal growth factor receptor (EGFR) therapy. Increased expression and glycosylation of immune checkpoint molecules …
BACKGROUND: Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limi …
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F, García-Castaño A, Vega N, Vega-Villegas ME, Gutiérrez-Sanz L. Rivera F, et al. Expert Rev Anticancer Ther. 2009 Oct;9(10):1421-8. doi: 10.1586/era.09.113. Expert Rev Anticancer Ther. 2009. PMID: 19828002
Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been shown to improve overall survival in patients with locally advanced SCCHN when combined with …
Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the head and neck (SCCHN). Cetuximab is …
Docetaxel.
Cortes JE, Pazdur R. Cortes JE, et al. J Clin Oncol. 1995 Oct;13(10):2643-55. doi: 10.1200/JCO.1995.13.10.2643. J Clin Oncol. 1995. PMID: 7595719 Review.
Responses were observed in breast, bronchial, and ovarian carcinomas. The recommended dose for phase II studies was 100 mg/m2 as a 1-hour intravenous (i.v.) infusion every 3 weeks. ...Corticosteroid premedication partially alleviated fluid retention seen after repeated doc …
Responses were observed in breast, bronchial, and ovarian carcinomas. The recommended dose for phase II studies was 100 mg/m2 as a 1- …
The 5-Ws of immunotherapy in head and neck cancer.
Botticelli A, Mezi S, Pomati G, Cerbelli B, Di Rocco C, Amirhassankhani S, Sirgiovanni G, Occhipinti M, Napoli V, Emiliani A, Mazzuca F, Tomao S, Nuti M, Marchetti P. Botticelli A, et al. Crit Rev Oncol Hematol. 2020 Sep;153:103041. doi: 10.1016/j.critrevonc.2020.103041. Epub 2020 Jun 30. Crit Rev Oncol Hematol. 2020. PMID: 32629362 Review.
The immune checkpoint inhibitors, a class of drugs able to block immune suppressive pathways in order to prime an anticancer immunity, revolutionized standard of care in platinum-refractory recurrent and/or metastatic head and neck carcinoma (R/M HNSCC). ...T …
The immune checkpoint inhibitors, a class of drugs able to block immune suppressive pathways in order to prime an anticancer immunity, revol …
Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
Guidi A, Codecà C, Ferrari D. Guidi A, et al. Med Oncol. 2018 Feb 13;35(3):37. doi: 10.1007/s12032-018-1096-5. Med Oncol. 2018. PMID: 29441454 Review.
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. ...Nowadays, the EXTREME regimen is the standard of care for the first-line treatment of recurrent/metastatic head and neck carcinoma (RMHNC). In …
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. ...Nowadays, the EXT …
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Cristina V, Herrera-Gómez RG, Szturz P, Espeli V, Siano M. Cristina V, et al. Int J Mol Sci. 2019 Oct 30;20(21):5399. doi: 10.3390/ijms20215399. Int J Mol Sci. 2019. PMID: 31671550 Free PMC article. Review.
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. ...In this review, we summarize the most important results regarding immune targeting agents for HNSCC, predictive biomarkers for resistan …
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. ...In …
228 results